Data from Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer
Ritu Chaudhary(Moffitt Cancer Center), Christine H. Chung(Moffitt Cancer Center), Antonio L. Amelio(University of North Carolina at Chapel Hill), José A. Guevara-Patiño(Moffitt Cancer Center), G. Getz, James W. Rocco(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Kedar Kirtane(Moffitt Cancer Center), Brian P. Danysh(Broad Institute), Michael J. Schell(University of Bonn), Robin Park(Moffitt Cancer Center), Samuel S. Freeman(Broad Institute), Nicholas J. Haradhvala(Broad Institute), Sowjanya Thatikonda(Johns Hopkins University), Yeva Meshkovska(Moffitt Cancer Center), Nabil Saba, Xiaofei Song(Moffitt Cancer Center), Jiannong Li, Juan Hernandez-Prera, Maria I. Biernacki, AikChoon Tan, Marcelo Bonomi, Graydon Moorhead, Robbert J.C. Slebos(University of Iowa)
Cited by 0